🟡 Preliminary Evidence
A case report from the Canadian Medical Association Journal describes the use of tenecteplase for thrombolysis in a 68-year-old woman presenting with acute ischemic stroke.
Key takeaways
- CMAJ case report documents tenecteplase use in acute ischemic stroke
- Patient was a 68-year-old woman treated for stroke symptoms
- Case adds to clinical experience with tenecteplase as potential alteplase alternative
Study at a Glance
| Source | CMAJ |
| Study type | Case report |
| Sample size | N = 1 |
| Population | 68-year-old woman with acute ischemic stroke |
| Country | Canada |
Tenecteplase vs Alteplase: Key Differences
Clinical characteristics of newer thrombolytic agent
Source: Clinical literature review | Georgian Medical Journal News
Clinical Presentation and Treatment Decision
According to the CMAJ case report, the publication details a 68-year-old woman with acute ischemic stroke symptoms who was treated with tenecteplase as the thrombolytic agent.
Tenecteplase offers several characteristics including single bolus administration and longer half-life compared to alteplase. These characteristics may influence treatment delivery in acute stroke settings.
Treatment Response and Case Documentation
The CMAJ case report documents the clinical experience with tenecteplase therapy in this patient. This adds to clinical experience with tenecteplase in acute stroke management.
The World Health Organization identifies stroke as a leading cause of death and disability globally.
Implications for Stroke Care
This case contributes to clinical experience with tenecteplase use in acute stroke care. Clinical experience with alternative thrombolytic agents may inform future treatment guidelines and protocols.
The simplified dosing regimen of tenecteplase could potentially affect implementation in various clinical settings. However, broader clinical trials and systematic evaluation remain necessary to establish definitive treatment recommendations.
Case report documents tenecteplase use in 68-year-old woman with acute ischemic stroke
— CMAJ case report (2024)
What this means
Frequently asked questions
What is tenecteplase?
Tenecteplase is a modified tissue plasminogen activator used for thrombolysis in acute ischemic stroke and myocardial infarction. It has characteristics including single bolus dosing and longer half-life compared to alteplase.
How does tenecteplase compare to alteplase?
Tenecteplase differs from alteplase in dosing regimen and pharmacologic properties including half-life and fibrin specificity.
Is tenecteplase approved for stroke treatment?
Regulatory approval varies by jurisdiction. Clinical trials and case experience continue to build evidence for tenecteplase use in acute ischemic stroke management.
Future research will likely focus on comparative effectiveness studies between tenecteplase and standard alteplase therapy. The accumulation of clinical case experience, as demonstrated in this CMAJ report, provides clinical documentation to complement trial data in stroke care.
Source: La tenecteplase pour la thrombolyse dun AVC ischemique aigu chez une femme de 68 ans
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
